Relapsed partially platinum sensitive Ovarian Cancer after end of 1st or

2nd-line platinum therapy

Group A:PLD 30 mg/m² + Carboplatin AUC 5 q4 wks

At PD, subsequent platinum rechallengeis mandatory

At PD, subsequent therapy at investigator discretion

Group B:PLD 30 mg/m2 +Trabectedin1.1 mg/m2

q3wks

R(1:1) Up to 6 cycles or PD

Primary Endpoint: Overall Survival

INOVATYONPhase III international, randomised study of Trabectedin plus Pegylated Liposomal

Doxorubicin (PLD) versus Carboplatin plus PLD in patients with relapsed ovarian cancer progressing within 6–12 months of last platinum

ENGOT model: aSponsor: Mario Negri Gynecologic Oncology Group; PI: Nicoletta Colombo

Accrual closed September 2017: 618 patients enrolled

Final Analysis planned for Q1 2020 (442 events )

2nd interim analysis at 2/3 of the events performed in Sept 2018 > green light to continue90% of planned OS events reached in October 2019